Massachusetts Financial Services Co. MA Has $2 Billion Stock Holdings in Pfizer Inc. (NYSE:PFE)

Massachusetts Financial Services Co. MA raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,207,521 shares of the biopharmaceutical company's stock after buying an additional 5,185,453 shares during the period. Massachusetts Financial Services Co. MA owned about 1.07% of Pfizer worth $1,997,083,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in PFE. Moneta Group Investment Advisors LLC lifted its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company's stock valued at $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter valued at about $3,150,472,000. Morgan Stanley raised its holdings in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company's stock valued at $4,073,547,000 after purchasing an additional 7,419,929 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 13.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company's stock valued at $3,097,341,000 after purchasing an additional 6,972,650 shares during the last quarter. Finally, National Bank of Canada FI raised its holdings in shares of Pfizer by 436.2% in the second quarter. National Bank of Canada FI now owns 8,206,790 shares of the biopharmaceutical company's stock valued at $300,736,000 after purchasing an additional 6,676,325 shares during the last quarter. 68.05% of the stock is owned by institutional investors.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 3,000 shares of the business's stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $26.47 per share, with a total value of $79,410.00. Following the purchase, the director now owns 9,000 shares of the company's stock, valued at $238,230. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Barclays lowered their target price on shares of Pfizer from $34.00 to $28.00 and set an "equal weight" rating for the company in a report on Thursday, December 14th. Morgan Stanley decreased their price objective on shares of Pfizer from $39.00 to $37.00 and set an "equal weight" rating for the company in a report on Wednesday, November 1st. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. Wells Fargo & Company decreased their price objective on shares of Pfizer from $39.00 to $35.00 and set an "equal weight" rating for the company in a report on Monday, October 16th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $36.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, October 16th. Eleven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average target price of $37.13.

Pfizer Price Performance

PFE stock opened at $26.93 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. Pfizer Inc. has a one year low of $25.76 and a one year high of $44.39. The stock has a market cap of $152.06 billion, a PE ratio of 74.81, a P/E/G ratio of 1.19 and a beta of 0.62. The firm has a 50 day simple moving average of $28.44 and a two-hundred day simple moving average of $31.74.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.61%. The business had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The business's quarterly revenue was down 41.3% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.23 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 26th will be paid a $0.42 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.24%. Pfizer's dividend payout ratio is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.